Cargando…

microRNA-371a-3p as informative biomarker for the follow-up of testicular germ cell cancer patients

PURPOSE: α-fetoprotein (AFP) and human chorionic gonadotropin subunit beta (B-HCG) are informative serum biomarkers for the primary diagnosis and follow-up of testicular germ cell cancer (TGCC) patients. About 20% of TGCC patients with a non-seminoma (NS) and about 80% with a seminoma (SE) are, howe...

Descripción completa

Detalles Bibliográficos
Autores principales: van Agthoven, Ton, Eijkenboom, Wil M. H., Looijenga, Leendert H. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537315/
https://www.ncbi.nlm.nih.gov/pubmed/28612337
http://dx.doi.org/10.1007/s13402-017-0333-9
_version_ 1783254150206717952
author van Agthoven, Ton
Eijkenboom, Wil M. H.
Looijenga, Leendert H. J.
author_facet van Agthoven, Ton
Eijkenboom, Wil M. H.
Looijenga, Leendert H. J.
author_sort van Agthoven, Ton
collection PubMed
description PURPOSE: α-fetoprotein (AFP) and human chorionic gonadotropin subunit beta (B-HCG) are informative serum biomarkers for the primary diagnosis and follow-up of testicular germ cell cancer (TGCC) patients. About 20% of TGCC patients with a non-seminoma (NS) and about 80% with a seminoma (SE) are, however, negative for these biomarkers. Embryonic stem cell microRNAs (miRs) may serve as promising alternative serum biomarkers. Here we investigated a retrospective series of serum samples from selected TGCC patients who developed a relapse in time to test the possible additional value of the serum-based ampTSmiR test compared to the conventional serum-based protein biomarkers for follow-up. METHODS: We investigated 261 retrospective serum samples of six selected fully evaluated TGCC patients with a proven relapse using the ampTSmiR test for miR-371a-3p, miR-373-3p, and miR-367-3p and compared the results to those of the conventional protein biomarkers. RESULTS: At primary diagnosis, elevated serum B-HCG, AFP and LDH levels were found to be informative in 4/6, 3/6 and 3/6 patients, respectively. At primary diagnosis the levels of miR-371a-3p and miR-373-3p were elevated in 4/4, and miR-367-3p in 3/4 patients. For two cases no starting serum sample was available for retrospective miR analysis. Residual disease (overlooked by histopathological examination) was detected in one case by miR-371a-3p only. The miR-371a-3p level was increased in one patient two months before detection of an intracranial metastasis. B-HCG was informative in 3/4 and the ampTSmiR test in 4/4 patients with a relapse or residual disease. None of the biomarkers were informative for the detection of residual mature teratoma. CONCLUSIONS: The ampTSmiR test is more sensitive than the conventional TGCC protein biomarkers for the detection of residual disease and relapse, excluding mature teratoma. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s13402-017-0333-9) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5537315
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer Netherlands
record_format MEDLINE/PubMed
spelling pubmed-55373152017-08-15 microRNA-371a-3p as informative biomarker for the follow-up of testicular germ cell cancer patients van Agthoven, Ton Eijkenboom, Wil M. H. Looijenga, Leendert H. J. Cell Oncol (Dordr) Original Paper PURPOSE: α-fetoprotein (AFP) and human chorionic gonadotropin subunit beta (B-HCG) are informative serum biomarkers for the primary diagnosis and follow-up of testicular germ cell cancer (TGCC) patients. About 20% of TGCC patients with a non-seminoma (NS) and about 80% with a seminoma (SE) are, however, negative for these biomarkers. Embryonic stem cell microRNAs (miRs) may serve as promising alternative serum biomarkers. Here we investigated a retrospective series of serum samples from selected TGCC patients who developed a relapse in time to test the possible additional value of the serum-based ampTSmiR test compared to the conventional serum-based protein biomarkers for follow-up. METHODS: We investigated 261 retrospective serum samples of six selected fully evaluated TGCC patients with a proven relapse using the ampTSmiR test for miR-371a-3p, miR-373-3p, and miR-367-3p and compared the results to those of the conventional protein biomarkers. RESULTS: At primary diagnosis, elevated serum B-HCG, AFP and LDH levels were found to be informative in 4/6, 3/6 and 3/6 patients, respectively. At primary diagnosis the levels of miR-371a-3p and miR-373-3p were elevated in 4/4, and miR-367-3p in 3/4 patients. For two cases no starting serum sample was available for retrospective miR analysis. Residual disease (overlooked by histopathological examination) was detected in one case by miR-371a-3p only. The miR-371a-3p level was increased in one patient two months before detection of an intracranial metastasis. B-HCG was informative in 3/4 and the ampTSmiR test in 4/4 patients with a relapse or residual disease. None of the biomarkers were informative for the detection of residual mature teratoma. CONCLUSIONS: The ampTSmiR test is more sensitive than the conventional TGCC protein biomarkers for the detection of residual disease and relapse, excluding mature teratoma. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s13402-017-0333-9) contains supplementary material, which is available to authorized users. Springer Netherlands 2017-06-13 2017 /pmc/articles/PMC5537315/ /pubmed/28612337 http://dx.doi.org/10.1007/s13402-017-0333-9 Text en © The Author(s) 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Paper
van Agthoven, Ton
Eijkenboom, Wil M. H.
Looijenga, Leendert H. J.
microRNA-371a-3p as informative biomarker for the follow-up of testicular germ cell cancer patients
title microRNA-371a-3p as informative biomarker for the follow-up of testicular germ cell cancer patients
title_full microRNA-371a-3p as informative biomarker for the follow-up of testicular germ cell cancer patients
title_fullStr microRNA-371a-3p as informative biomarker for the follow-up of testicular germ cell cancer patients
title_full_unstemmed microRNA-371a-3p as informative biomarker for the follow-up of testicular germ cell cancer patients
title_short microRNA-371a-3p as informative biomarker for the follow-up of testicular germ cell cancer patients
title_sort microrna-371a-3p as informative biomarker for the follow-up of testicular germ cell cancer patients
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537315/
https://www.ncbi.nlm.nih.gov/pubmed/28612337
http://dx.doi.org/10.1007/s13402-017-0333-9
work_keys_str_mv AT vanagthoventon microrna371a3pasinformativebiomarkerforthefollowupoftesticulargermcellcancerpatients
AT eijkenboomwilmh microrna371a3pasinformativebiomarkerforthefollowupoftesticulargermcellcancerpatients
AT looijengaleenderthj microrna371a3pasinformativebiomarkerforthefollowupoftesticulargermcellcancerpatients